132 related articles for article (PubMed ID: 19546522)
1. A comparison of mycophenolate mofetil with ciclosporine for the treatment of chronic plaque-type psoriasis.
Beissert S; Pauser S; Sticherling M; Frieling U; Loske KD; Frosch PJ; Haase I; Luger TA
Dermatology; 2009; 219(2):126-32. PubMed ID: 19546522
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis.
Akhyani M; Chams-Davatchi C; Hemami MR; Fateh S
J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1447-51. PubMed ID: 20384673
[TBL] [Abstract][Full Text] [Related]
3. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin.
Pedraz J; Daudén E; Delgado-Jiménez Y; García-Río I; García-Díez A
J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):702-6. PubMed ID: 16836499
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients.
Geilen CC; Arnold M; Orfanos CE
Br J Dermatol; 2001 Mar; 144(3):583-6. PubMed ID: 11260019
[TBL] [Abstract][Full Text] [Related]
5. Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis.
Daudén E; Sánchez-Peinado C; Ruiz-Genao D; García-F-Villalta M; Onate MJ; García-Díez A
Br J Dermatol; 2004 Jan; 150(1):132-5. PubMed ID: 14746627
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil (CellCept) for psoriasis: a two-center, prospective, open-label clinical trial.
Zhou Y; Rosenthal D; Dutz J; Ho V
J Cutan Med Surg; 2003; 7(3):193-7. PubMed ID: 12704533
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study.
Colombo D; Cassano N; Altomare G; Giannetti A; Vena GA
Int J Immunopathol Pharmacol; 2010; 23(4):1143-52. PubMed ID: 21244763
[TBL] [Abstract][Full Text] [Related]
8. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
Kwinta-Rybicka J; Wilkosz K; Wierzchowska-Słowiacze EK; Ogarek I; Moczulska A; Stec Z; Pełkowska A; Sancewicz-Pach K; Pietrzyk JA
Przegl Lek; 2006; 63 Suppl 3():44-8. PubMed ID: 16898486
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study.
Abramowicz D; Del Carmen Rial M; Vitko S; del Castillo D; Manas D; Lao M; Gafner N; Wijngaard P;
J Am Soc Nephrol; 2005 Jul; 16(7):2234-40. PubMed ID: 15917338
[TBL] [Abstract][Full Text] [Related]
10. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center.
Fujinaga S; Ohtomo Y; Hirano D; Nishizaki N; Someya T; Ohtsuka Y; Kaneko K; Shimizu T
Clin Nephrol; 2009 Oct; 72(4):268-73. PubMed ID: 19825332
[TBL] [Abstract][Full Text] [Related]
12. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of mycophenolate mofetil and cyclosporine: a review.
Buell C; Koo J
J Drugs Dermatol; 2008 Aug; 7(8):741-8. PubMed ID: 18720690
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of mycophenolic acid in patients with psoriasis.
Daudén E; Pedraz J; Alvarez-Ruiz S; García-Río I; Sánchez-Peinado C; Oñate MJ; García-Diez A
Eur J Dermatol; 2010; 20(3):321-2. PubMed ID: 20146966
[TBL] [Abstract][Full Text] [Related]
15. Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis.
Davison SC; Morris-Jones R; Powles AV; Fry L
Br J Dermatol; 2000 Aug; 143(2):405-7. PubMed ID: 10951153
[TBL] [Abstract][Full Text] [Related]
16. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study.
Thaçi D; Bräutigam M; Kaufmann R; Weidinger G; Paul C; Christophers E
Dermatology; 2002; 205(4):383-8. PubMed ID: 12444336
[TBL] [Abstract][Full Text] [Related]
17. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.
Gottlieb AB; Griffiths CE; Ho VC; Lahfa M; Mrowietz U; Murrell DF; Ortonne JP; Todd G; Cherill R; Marks I; Emady-Azar S; Paul CF;
Br J Dermatol; 2005 Jun; 152(6):1219-27. PubMed ID: 15948985
[TBL] [Abstract][Full Text] [Related]
18. Psoriasis vulgaris treated successfully with mycophenolate mofetil.
Haufs MG; Beissert S; Grabbe S; Schütte B; Luger TA
Br J Dermatol; 1998 Jan; 138(1):179-81. PubMed ID: 9536244
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.
Vena GA; Galluccio A; Pezza M; Vestita M; Cassano N
J Dermatolog Treat; 2012 Aug; 23(4):255-60. PubMed ID: 21756153
[TBL] [Abstract][Full Text] [Related]
20. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
